文献速递妇科

子宫内膜癌实践差异及通过分子分型改善医疗公平的潜力

Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification.
PubMed 文献 · Gynecol Oncol · 2022-03-01

研究评估加拿大10家三级癌症中心和19家社区中心在2016年诊断的1336例子宫内膜癌患者的全程管理差异,并回顾性进行ProMisE分子分型。结果显示手术、影像、辅助治疗及遗传咨询转诊存在显著实践差异,分子分型与生存显著相关,按2020年ESGO/ESTRO/ESP指南约有10%队列的辅助治疗方向会改变。

要点

  • 三级中心淋巴结清扫率在1-2级与3级肿瘤分别为平均57%和82%,大网膜取样分别为20%和79%。
  • 高危子宫内膜癌辅助化疗使用率范围0-55%,辅助放化疗范围64-100%。
  • 回顾性分子分型检出6% POLEmut、28% MMRd、48% NSMP和18% p53abn,与生存显著相关。

核心结论

  • 分子分型有潜力减轻当前子宫内膜癌诊疗中的巨大实践差异,实现可重复的风险评估、指导治疗并减少医疗 disparities。

研究设计与样本

  • 研究纳入加拿大10家三级癌症中心(n=1022)和19家社区中心(n=314)共1336例完全可评估的2016年诊断的子宫内膜癌患者,收集肿瘤样本和临床数据,并回顾性进行ProMisE分子分型。

主要发现

  • 三级中心手术实践差异显著:淋巴结清扫率范围14-100%(1-2级平均57%,3级82%),大网膜取样率1-2级平均20%、3级79%。
  • 术前CT扫描获取不一致(1-2级平均32%,3级51%),高危子宫内膜癌辅助化疗使用率范围0-55%,辅助放化疗范围64-100%。
  • 回顾性分子分型显示6% POLEmut、28% MMRd、48% NSMP和18% p53abn,且与生存显著相关。
  • 回顾性诊断为MMRd子宫内膜癌的患者中仅22%曾转诊至遗传性癌症项目。
  • p53abn子宫内膜癌患者中21%未行淋巴结清扫、23%未行大网膜取样,41%未接受化疗。

关键数值与推荐

  • 与2020年ESGO/ESTRO/ESP指南比较,2016年管理队列中分别有至少26例和95例患者会被导向更少或更多辅助治疗(占队列10%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 分子分型为回顾性进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We measured the variation in practice across all aspects of endometrial cancer (EC) management and assessed the potential impact of implementation of molecular classification. METHODS: Centers from across Canada provided representative tumor samples and clinical data, including preoperative workup, operative management, hereditary cancer program (HCP) referrals, adjuvant therapy, surveillance and outcomes, for all EC patients diagnosed in 2016. Tumors were classified into the four ProMisE molecular subtypes. RESULTS: A total of 1336 fully evaluable EC patients were identified from 10 tertiary cancer centers (TC; n = 1022) and 19 community centers (CC; n = 314). Variation of surgical practice across TCs was profound (14-100%) for lymphadenectomy (LND) (mean 57% Gr1/2, 82% Gr3) and omental sampling (20% Gr1/2, 79% Gr3). Preoperative CT scans were inconsistently obtained (mean 32% Gr1/2, 51% Gr3) and use of adjuvant chemo or chemoRT in high risk EC ranged from 0-55% and 64-100%, respectively. Molecular subtyping was performed retrospectively and identified 6% POLEmut, 28% MMRd, 48% NSMP and 18% p53abn ECs, and was significantly associated with survival. Within patients retrospectively diagnosed with MMRd EC only 22% had been referred to HCP. Of patients with p53abn EC, LND and omental sampling was not performed in 21% and 23% respectively, and 41% received no chemotherapy. Comparison of management in 2016 with current 2020 ESGO/ESTRO/ESP guidelines identified at least 26 and 95 patients that would have been directed to less or more adjuvant therapy, respectively (10% of cohort). CONCLUSION: Molecular classification has the potential to mitigate the profound variation in practice demonstrated in current EC care, enabling reproducible risk assessment, guiding treatment and reducing health care disparities.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Jamieson A, Huvila J, Thompson EF, et al. Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification. Gynecol Oncol. 2022. PMID: 35246332. doi:10.1016/j.ygyno.2022.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。